WO1995003808A1 - Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel - Google Patents

Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel Download PDF

Info

Publication number
WO1995003808A1
WO1995003808A1 PCT/EP1994/002477 EP9402477W WO9503808A1 WO 1995003808 A1 WO1995003808 A1 WO 1995003808A1 EP 9402477 W EP9402477 W EP 9402477W WO 9503808 A1 WO9503808 A1 WO 9503808A1
Authority
WO
WIPO (PCT)
Prior art keywords
sucralphate
antiacid
gel
pharmaceutical compositions
compositions according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1994/002477
Other languages
French (fr)
Inventor
Giorgio Zagnoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lisapharma SpA
Original Assignee
Lisapharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lisapharma SpA filed Critical Lisapharma SpA
Priority to EP94925401A priority Critical patent/EP0715520B1/en
Priority to US08/591,647 priority patent/US5661137A/en
Priority to DE69425061T priority patent/DE69425061D1/en
Priority to AT94925401T priority patent/ATE194079T1/en
Priority to AU75333/94A priority patent/AU7533394A/en
Publication of WO1995003808A1 publication Critical patent/WO1995003808A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates

Definitions

  • the present invention relates to antiacid pharmaceutical compositions in the form of suspensions containing sucralphate gel as an active ingredient combined with suitable excipients and/or diluents.
  • Sucralphate i.e. the complex of sulphated sucrose and aluminium hydroxide, is an antiulcer drug. It exerts an inhibitory action against pepsin and, as more recently found, a cytoprotective action.
  • sucralphate reacts with the acids of the stomach giving a tacky mucosa-adhesive substance, denominated paste.
  • Said tacky substance is deemed essential to secure the antiulcer activity of sucralphate: it adheres to the ulcers and maintains the pH of the gastric microenvironment at ideal values for pepsin activity inhibition.
  • sucralphate in powder form rapidly becomes tacky and adhesive, and yields approx. 10# of its antiacid power within 2 to 3 minutes. After said initial yield, even if the reaction medium is maintained under vigorous stirring, the reaction with the acid becomes very slow as it is hindered by the paste viscosity.
  • sucralphate is suitable for the treatment of ulcers, it cannot be used as an antiacid.
  • the therapeutic activity of an antiacid preparation depends not only on its absolute acidity neutralization, but also and especially on its acidity neutralization rate in the gastric environment.
  • Advanced pharmacopoeias state that the therapeutic activity of an antiacid preparation is a function of two basic parameters: reaction rate and neutralization duration.
  • the first parameter i.e. the reaction rate
  • the second parameter i.e. neutralization duration
  • sucralphate exerts a poor action: paste formation considerably slows down its reactivity and, therefore, a pH value compatible with pyrosis suppression cannot be obtained.
  • sucralphate is unable to maintain the pH value reached for an appropriate time: theoretically it can maintain the gastric environment buffered, but in fact, against a continuous secretion of the gastric juice, it does not exert any buffering action due to the low reactivity of the paste that formed.
  • sucralphate can exert an antiacid action only if chemically transformed into a specific antiacid product , as disclosed in EP 437406. Therefore , sucralphate powder cannot constitute an efficacious active ingredient of an antiacid preparation.
  • EP 286978 by the Applicant discloses sucralphate in the form of gel , with particles dimensional distribution practically at the limit of colloidal size , which secures a very high specific surface of the product.
  • Sucralphate gel exerts a more potent antiulcer action than the powder form of general use and, when contacted with acids, does not form the paste already mentioned.
  • the higher activity of the product was proved to result from its specific ability to adhere to the mucosa, i.e. from the bioadhesion, taking place without any intervention of the acids.
  • sucralphate gel aqueous suspension shows unique thixotropic-type Theological properties revealing a considerable surface activity of the particles, which very easily gives rise to interactions both with one another and with the biological substrates.
  • Fig. 1 illustrates the change of pH on addition of 0.5N HC1 to 1 g of sucralphate gel and, respectively, sucralphate powder at 25°C.
  • Fig. 2 shows the antiacid effectiveness by Rosset-Rice's test and the results obtained with antiacid doses as per Examples 1, 2, 3, Fig. shows the antiacid effectiveness by Rosset-Rice's test and the results obtained by testing doses of 1 g sucralphate powder, 1 g of sucralphate gel, and 2 g of sucralphate powder.
  • sucralphate gel shows a rate of reaction with the acids and acidity neutralization power decidedly superior to sucralphate in the powder form, as elucidated in Fig. 1.
  • This figure illustrates the change of pH on addition of 0.5N HC1 to 1 g of sucralphate gel and, respectively, sucralphate powder at 25°C.
  • an antiacid preparation is generally considered safe and effective when it obeys the safety and effectiveness requirements ("Antiacid Effectiveness" requirements).
  • Antiacid Effectiveness requirements
  • the product has to pass a preliminary test meant to establish whether it may be defined antiacid or not. Said test consists in causing a single minimum dose of substance supposed to be antiacid to react with 0.5N hydrochloric acid for 10 minutes. Should the substance being tested under such conditions be capable of bringing the solution pH to values above 3-5. the preparation will be considered antiacid.
  • sucralphate gel at 37°C shows an acidity neutralization rate allowing it to pass the USP XXII preliminary test.
  • sucralphate gel content in the suspension preferably ranges from 10 to 20% w/v.
  • the therapeutic compositions of the present invention contain 1.5 to 4 g sucralphate per dosage unit and, preferably, 2 g sucralphate per dosage unit.
  • sucralphate gel is self-suspending: in other words, no other suspending agent is needed to obtain stable suspensions. Therefore, sucralphate gel can be used as a suspending agent to prepare antiacid suspensions in which other antiacids are stably suspended.
  • sucralphate gel as a suspending agent allows obtaining a safe and effective sucralphate-based antiacid preparation matching two important goals.
  • sucralphate gel may be strengthened by the addition of a dose of another antiacid with the result that a more potent antiacid action is obtained.
  • another antiacid active ingredient such as for example magnesium hydroxide or salts thereof
  • the claimed compositions may also contain another conventional antiacid, if any, said antiacid being preferably selected among magnesium hydroxide, magnesium carbonate and calcium carbonate. In this case, 1 g of sucralphate was found to be sufficient for an optimal antiacid-suspending effect.
  • sucralphate when combined with another antiacid active ingredient, preferably ranges from 1 to 3 S and the dose of said antacid active ingredient ranges from 0.250 to 0.750 g.
  • the following examples of antiacid preparations obtained according to the present invention are conveyed by way of indication, not of limitation.
  • One 10 ml dose of suspension contains:
  • One 15 ml dose of suspension contains:
  • Gastroenterology, 26, 940, 1954 was also conducted on the preparations of the present invention further to prove the effectiveness of the antiacid dose of same.
  • a 400 ml beaker containing water (70 ml) and 0.1N HC1 (30 ml) maintained at 37°C was fed with a dose of antiacid.
  • 2 ml/min of ION HC1 the change in pH was measured under continuous magnetic stirring (300 rpm/min) .
  • the antiacid dose is considered effective when a pH value of 3-0 is reached within 10 minutes and maintained above said value for over one hour.
  • the Rosset-Rice's test provided evidence that all products possessed antiacid effectiveness.
  • Sucralphate gel at a dose of 1 g shows some antiacid power and sucralphate powder at a dose of 2 g reaches a pH value of 3 within 10 minutes, but cannot maintain said value for over 15 minutes, during which 2 ml/min HC1 was added to simulate gastric secretion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Antiacid pharmaceutical compositions in the form of suspensions containing sucralphate gel as an active ingredient combined with suitable excipients and/or diluents.

Description

ANTIACID PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUSPENSION BASED ON SUCRALPHATE GEL Field of the invention
The present invention relates to antiacid pharmaceutical compositions in the form of suspensions containing sucralphate gel as an active ingredient combined with suitable excipients and/or diluents.
State of the art
Sucralphate, i.e. the complex of sulphated sucrose and aluminium hydroxide, is an antiulcer drug. It exerts an inhibitory action against pepsin and, as more recently found, a cytoprotective action.
In the solid state, sucralphate reacts with the acids of the stomach giving a tacky mucosa-adhesive substance, denominated paste. Said tacky substance is deemed essential to secure the antiulcer activity of sucralphate: it adheres to the ulcers and maintains the pH of the gastric microenvironment at ideal values for pepsin activity inhibition.
Due to sucralphate basicity, 1 g of product can neutralize approx.
13 mEq hydrogen ions. On addition to 0.1 N hydrochloric acid, sucralphate in powder form rapidly becomes tacky and adhesive, and yields approx. 10# of its antiacid power within 2 to 3 minutes. After said initial yield, even if the reaction medium is maintained under vigorous stirring, the reaction with the acid becomes very slow as it is hindered by the paste viscosity.
Therefore, although sucralphate is suitable for the treatment of ulcers, it cannot be used as an antiacid.
In fact, as well known to those skilled in the art, the therapeutic activity of an antiacid preparation depends not only on its absolute acidity neutralization, but also and especially on its acidity neutralization rate in the gastric environment.
Advanced pharmacopoeias state that the therapeutic activity of an antiacid preparation is a function of two basic parameters: reaction rate and neutralization duration.
The first parameter, i.e. the reaction rate, concerns acidity neutralization for a fast relief of the heartburn sensation (pyrosis) generally accompanying gastric hyperacidity; the second parameter, i.e. neutralization duration, concerns the development of a buffer action maintaining for an appropriate time the gastric lumen pH above the value at which said painful sensation is no more felt.
As concerns the first parameter, sucralphate exerts a poor action: paste formation considerably slows down its reactivity and, therefore, a pH value compatible with pyrosis suppression cannot be obtained. As concerns the second parameter, sucralphate is unable to maintain the pH value reached for an appropriate time: theoretically it can maintain the gastric environment buffered, but in fact, against a continuous secretion of the gastric juice, it does not exert any buffering action due to the low reactivity of the paste that formed.
It follows that sucralphate can exert an antiacid action only if chemically transformed into a specific antiacid product , as disclosed in EP 437406. Therefore , sucralphate powder cannot constitute an efficacious active ingredient of an antiacid preparation.
EP 286978 by the Applicant discloses sucralphate in the form of gel , with particles dimensional distribution practically at the limit of colloidal size , which secures a very high specific surface of the product.
Sucralphate gel exerts a more potent antiulcer action than the powder form of general use and, when contacted with acids, does not form the paste already mentioned. The higher activity of the product was proved to result from its specific ability to adhere to the mucosa, i.e. from the bioadhesion, taking place without any intervention of the acids.
The sucralphate gel aqueous suspension shows unique thixotropic-type Theological properties revealing a considerable surface activity of the particles, which very easily gives rise to interactions both with one another and with the biological substrates. Brief description of the drawings
Fig. 1 illustrates the change of pH on addition of 0.5N HC1 to 1 g of sucralphate gel and, respectively, sucralphate powder at 25°C. Fig. 2 shows the antiacid effectiveness by Rosset-Rice's test and the results obtained with antiacid doses as per Examples 1, 2, 3, Fig. shows the antiacid effectiveness by Rosset-Rice's test and the results obtained by testing doses of 1 g sucralphate powder, 1 g of sucralphate gel, and 2 g of sucralphate powder. Summary of the Invention
It has surprisingly been found that sucralphate gel shows a rate of reaction with the acids and acidity neutralization power decidedly superior to sucralphate in the powder form, as elucidated in Fig. 1. This figure illustrates the change of pH on addition of 0.5N HC1 to 1 g of sucralphate gel and, respectively, sucralphate powder at 25°C.
It is an object of the present invention to provide antiacid pharmaceutical compositions in the form of suspensions containing sucralphate gel as an active ingredient, combined with suitable excipients and/or diluents, particularly suitable for the treatment of pyrosis and gastroesophageal backflow. Detailed description of the invention
According to US Pharmacopoeia USP XXII, an antiacid preparation is generally considered safe and effective when it obeys the safety and effectiveness requirements ("Antiacid Effectiveness" requirements). To meet said requirements, the product has to pass a preliminary test meant to establish whether it may be defined antiacid or not. Said test consists in causing a single minimum dose of substance supposed to be antiacid to react with 0.5N hydrochloric acid for 10 minutes. Should the substance being tested under such conditions be capable of bringing the solution pH to values above 3-5. the preparation will be considered antiacid.
Should said preliminary test give positive results, a second test will be conducted to determine the acidity neutralization power of the substance. Said power must be such that the aforesaid single minimum dose of the substance supposed to be antiacid can neutralize at least 5 mEq of acid.
It has surprisingly been found by the Applicant that sucralphate gel at 37°C shows an acidity neutralization rate allowing it to pass the USP XXII preliminary test.
In particular, in the preliminary antiacid effectiveness test as per USP XXII, already a dose of 1.5 g brings pH to values exceeding 3-5. In the second antiacid test, which is meant to determine the neutralization power, the said dose was found to neutralize 23 mEq against the limit value of 20 to 25 mEq set by USP XXII.
Vice versa, in the preliminary test, the same dose of product containing commercially available sucralphate powder gives pH values ranging from 1.2 to 1.6. Evidence is thus provided that sucralphate powder is unable to exert an antiacid action. The sucralphate gel content in the suspension preferably ranges from 10 to 20% w/v.
In particular, the therapeutic compositions of the present invention contain 1.5 to 4 g sucralphate per dosage unit and, preferably, 2 g sucralphate per dosage unit. Furthermore in water dispersion sucralphate gel is self-suspending: in other words, no other suspending agent is needed to obtain stable suspensions. Therefore, sucralphate gel can be used as a suspending agent to prepare antiacid suspensions in which other antiacids are stably suspended. The use of sucralphate gel as a suspending agent allows obtaining a safe and effective sucralphate-based antiacid preparation matching two important goals. First, the antiacid action of sucralphate gel may be strengthened by the addition of a dose of another antiacid with the result that a more potent antiacid action is obtained. Second, the use of sucralphate in conjunction with another antiacid active ingredient, such as for example magnesium hydroxide or salts thereof, brings a therapeutic benefit: i.e. the astringent effect on the intestine function typical of sucralphate is limited by the laxative effect typical of magnesium salts. It follows that the claimed compositions may also contain another conventional antiacid, if any, said antiacid being preferably selected among magnesium hydroxide, magnesium carbonate and calcium carbonate. In this case, 1 g of sucralphate was found to be sufficient for an optimal antiacid-suspending effect.
The preferred dose of sucralphate, when combined with another antiacid active ingredient, preferably ranges from 1 to 3 S and the dose of said antacid active ingredient ranges from 0.250 to 0.750 g. The following examples of antiacid preparations obtained according to the present invention are conveyed by way of indication, not of limitation. EXAMPLE 1
One 10 ml dose of suspension contains:
Sucralphate gel (corresponding to 927 sag Al(OH)o) 1.500 g Methyl-p-hydroxybenzoate sodium salt 0.020 g
Propyl-p-hydroxybenzoate sodium salt 0.010 g
Sorbitol 70 2.700 g
Apple flavouring 0.014 g
Purified water q.s. p-Hydroxybenzoates were dispersed in liquid sorbitol and wet sucralphate gel was added. The resulting mixture was dispersed to give a thick and fluid cream, which was added with the flavouring agent, made up to volume with water, turbine-stirred without air embodiment, to yield a fluid and translucent suspension. EXAMPLE 2
One 15 ml dose of suspension contains:
Sucralphate gel (corresponding to 1,324 mg Al(OH) ) 2.000 g Methyl-p-hydroxybenzoate sodium salt 0.030 g
Propyl-p-hydroxybenzoate sodium salt 0.015 g Sorbitol 70 4.600 g
Apple flavouring 0.014 g
Purified water q.s.
This suspension was prepared according to Example 1. EXAMPLE 3 One 7ό ml dose of suspension contains: Sucralphate gel (corresponding to 662 mg Al(OH)n) 1.000 g Magnesium hydroxide 0.281 g
Methyl-p-hydroxybenzoate sodium salt 0.016 g
Propyl-p-hydroxybenzoate sodium salt 0.008 g Sorbitol 70% 2.300 g
Apple flavouring 0.014 g
Purified water q.s.
This suspension was prepared according to Example 1. EXAMPLE 4 One 7-5 ml dose of suspension contains:
Sucralphate gel (corresponding to 662 mg Al(OH)o) 1.000 g Magnesium carbonate 0.400 g
Methyl-p-hydroxybenzoate sodium salt 0.016 g
Propyl-p-hydroxybenzoate sodium salt 0.080 g Sorbitol 70 2.300 g
Apple flavouring 0.014 g
Purified water q.s.
This suspension was prepared according to Example 1. The test as per USP XXII conducted on the formulation of Example 1 for the determination of the antiacid effectiveness gave the following results: preliminary antiacid power (pH > 3-5): pH 3- neutralization power (>20.25 mEq): 23 mEq. The test as per USP XXII conducted on the formulation of Example 2 for the determination of the antiacid effectiveness gave the following results: preliminary antiacid power (pH > 3-5) : pH 3•85 neutralization power (>28.93 mEq): 27 mEq.
The test as per USP XXII conducted on the formulation of Example 3 for the determination of the antiacid effectiveness gave the following results: preliminary antiacid power (pH > 3 - 5) '• pH 5-6 neutralization power (>21.73 mEq): 27.0 mEq.
The test as per USP XXII conducted on the formulation of Example 4 for the determination of the antiacid effectiveness gave the following results: preliminary antiacid power (pH > 3-5): pH 5-6 neutralization power (>21.8 mEq): >28.3 mEq.
ROSSET-RICE DYNAMIC TEST Rosset-Rice's dynamic test (N.E. Rosset and M.L. Rice,
Gastroenterology, 26, 940, 1954) was also conducted on the preparations of the present invention further to prove the effectiveness of the antiacid dose of same. According to this test, a 400 ml beaker containing water (70 ml) and 0.1N HC1 (30 ml) maintained at 37°C was fed with a dose of antiacid. After addition of 2 ml/min of ION HC1 the change in pH was measured under continuous magnetic stirring (300 rpm/min) .
The antiacid dose is considered effective when a pH value of 3-0 is reached within 10 minutes and maintained above said value for over one hour. With reference to the figures, the Rosset-Rice's test provided evidence that all products possessed antiacid effectiveness. Sucralphate gel at a dose of 1 g shows some antiacid power and sucralphate powder at a dose of 2 g reaches a pH value of 3 within 10 minutes, but cannot maintain said value for over 15 minutes, during which 2 ml/min HC1 was added to simulate gastric secretion.

Claims

CLAIMS 1. Antiacid pharmaceutical compositions in the form of suspensions containing sucralphate gel as an active ingredient combined with suitable excipients and/or diluents. 2. The pharmaceutical compositions according to claim 1 suitable for the treatment of pyrosis and gastroesophageal backflow. 3- The pharmaceutical compositions according to claim 1 wherein the sucralphate gel content in the suspension preferably ranges from 10 to 20% w/v. 4. The pharmaceutical compositions according to claim 1 wherein the amount of sucralphate per dosage unit ranges from 1.5 to 4 g. 5- The pharmaceutical compositions according to claim 4 wherein the amount of sucralphate per dosage unit is 2 g. 6. The pharmaceutical compositions according to claim 1 wherein another antiacid active ingredient of the conventional type, if any, is also present. 7- The pharmaceutical compositions according to claim 6 wherein the other antiacid agent is selected among magnesium hydroxide, magnesium carbonate and calcium carbonate. 8. The pharmaceutical compositions according to claim 6 wherein the dose of sucralphate gel ranges from 1 to 3 S and the dose of the other antiacid active ingredient ranges from 0.250 to 0.750 g per dosage unit.
PCT/EP1994/002477 1993-07-30 1994-07-27 Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel Ceased WO1995003808A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP94925401A EP0715520B1 (en) 1993-07-30 1994-07-27 Use of a suspension based on sucralphate gel as antacid
US08/591,647 US5661137A (en) 1993-07-30 1994-07-27 Antacid pharmaceutical composition in the form of a suspension based on sucralfate gel
DE69425061T DE69425061D1 (en) 1993-07-30 1994-07-27 USE OF SUSPENSION BASED ON SUCRAL FATGEL AS ANTAZID
AT94925401T ATE194079T1 (en) 1993-07-30 1994-07-27 USE OF A SUSPRALFATGEL-BASED SUSPENSION AS AN ANTACID
AU75333/94A AU7533394A (en) 1993-07-30 1994-07-27 Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI93A001742 1993-07-30
IT93MI001742A IT1264546B1 (en) 1993-07-30 1993-07-30 PHARMACEUTICAL COMPOSITION WITH ANTI-ACID ACTIVITY IN THE FORM OF A SUCRALFATE GEL-BASED SUSPENSION

Publications (1)

Publication Number Publication Date
WO1995003808A1 true WO1995003808A1 (en) 1995-02-09

Family

ID=11366756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002477 Ceased WO1995003808A1 (en) 1993-07-30 1994-07-27 Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel

Country Status (7)

Country Link
US (1) US5661137A (en)
EP (1) EP0715520B1 (en)
AT (1) ATE194079T1 (en)
AU (1) AU7533394A (en)
DE (1) DE69425061D1 (en)
IT (1) IT1264546B1 (en)
WO (1) WO1995003808A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019066A4 (en) * 1996-10-04 2000-07-19 Merck & Co Inc METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ESTOMAC BURNS

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2264822C1 (en) * 2004-09-21 2005-11-27 Назаренко Павел Владимирович Preparation of anti-ulcerous and antacidal action
US10716802B2 (en) 2013-03-15 2020-07-21 The Brigham And Women's Hospital, Inc. Compounds to modulate intestinal absorption of nutrients
WO2017053970A1 (en) 2015-09-24 2017-03-30 The Brigham And Women's Hospital, Inc. Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245855A2 (en) * 1986-05-16 1987-11-19 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparations for application on esophagus mucosa
EP0286978A1 (en) * 1987-04-15 1988-10-19 Lisapharma Spa Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents
EP0331385A2 (en) * 1988-03-02 1989-09-06 Chugai Pharmaceutical Co., Ltd. Aqueous suspension of sucralfate
EP0403048A2 (en) * 1989-06-14 1990-12-19 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
EP0437406A1 (en) * 1990-01-12 1991-07-17 Pierre Fabre Medicament Pharmaceutical composition in stable aqueous suspension form containing sucralfate and anti-acidic substance as well as process for preparing it
EP0511703A2 (en) * 1991-04-25 1992-11-04 Apr Applied Pharma Research S.A. Pharmaceutical composition, containing sucralfate and carrageenan, useful for gastroenterology
WO1993011750A1 (en) * 1991-12-17 1993-06-24 Fuisz Technologies Ltd. Ulcer prevention and treatment composition and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230157B (en) * 1989-06-16 1991-10-14 Lisapharma Spa USE OF WET SUCRALPHATE FOR THE TREATMENT OF DERMA ULCERS AND AS A VEHICLE OF DRUGS WITH TOPICAL ACTIVITY

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245855A2 (en) * 1986-05-16 1987-11-19 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparations for application on esophagus mucosa
EP0286978A1 (en) * 1987-04-15 1988-10-19 Lisapharma Spa Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents
EP0331385A2 (en) * 1988-03-02 1989-09-06 Chugai Pharmaceutical Co., Ltd. Aqueous suspension of sucralfate
EP0403048A2 (en) * 1989-06-14 1990-12-19 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
EP0437406A1 (en) * 1990-01-12 1991-07-17 Pierre Fabre Medicament Pharmaceutical composition in stable aqueous suspension form containing sucralfate and anti-acidic substance as well as process for preparing it
EP0511703A2 (en) * 1991-04-25 1992-11-04 Apr Applied Pharma Research S.A. Pharmaceutical composition, containing sucralfate and carrageenan, useful for gastroenterology
WO1993011750A1 (en) * 1991-12-17 1993-06-24 Fuisz Technologies Ltd. Ulcer prevention and treatment composition and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REYNOLDS J.E.F.: "MARTINDALE-THE EXTRA PHARMACOPOEIA", 1990, PHARMACEUTICAL PRESS, LONDON GB, 165640 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019066A4 (en) * 1996-10-04 2000-07-19 Merck & Co Inc METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ESTOMAC BURNS

Also Published As

Publication number Publication date
US5661137A (en) 1997-08-26
IT1264546B1 (en) 1996-10-02
ATE194079T1 (en) 2000-07-15
ITMI931742A0 (en) 1993-07-30
DE69425061D1 (en) 2000-08-03
EP0715520B1 (en) 2000-06-28
ITMI931742A1 (en) 1995-01-30
EP0715520A1 (en) 1996-06-12
AU7533394A (en) 1995-02-28

Similar Documents

Publication Publication Date Title
US5667802A (en) Antacid composition
JPH0535130B2 (en)
US5260304A (en) Pharmaceutical preparation binding with gastric acid
US4869902A (en) Antacid composition
US4252790A (en) Method for treating gastric ulcer-prone patients
AU2011242177B8 (en) A solid pharmaceutical composition for neutralizing stomach acid
US4704278A (en) Fluidized magaldrate suspension
AU578690B2 (en) Antacid composition
JPS61275220A (en) Novel pharmaceutical composition
US5360793A (en) Rafting antacid formulation
EP0007619A2 (en) Galactomannan polysaccharide gum formulation containing gellation inhibitor
US4465667A (en) Process for the preparation of gastric acid neutralizing agents, gastric acid neutralizing agents, and a method for treating hyperacidity and disorders related thereto
US5661137A (en) Antacid pharmaceutical composition in the form of a suspension based on sucralfate gel
JPH06502855A (en) Composition containing antihistamine H↓2 receptor antagonist and bioadhesive
Brody et al. Antacids I. Comparative biochemical and economic considerations
EP0136006B1 (en) Pharmaceutical compositions
EP0814773B1 (en) Pectin liquid pharmaceutical compositions
EP0814772B1 (en) Pectin pharmaceutical compositions
US9138406B2 (en) Composition for combating epistaxis
US4216207A (en) Method and composition for treatment of gastro-duodenal ulcers
JPH07103037B2 (en) Rehydratable magaldrate composition
CA1252045A (en) Fluidized magaldrate suspension
JPS63503541A (en) Method for producing pharmaceutical formulations with high gastric acid binding capacity, delayed effect and high bioavailability
MXPA96002270A (en) Orally applicable pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994925401

Country of ref document: EP

Ref document number: 08591647

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1994925401

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1994925401

Country of ref document: EP